Abstract
Objective
To detect the expressions of E-cadherin, α-catenin and β-catenin and analyze the relationship between E-cadherin-catenin adhesion complex and clinicopathological features in breast cancer.
Methods
The expressions of E-cadherin, α-cadherin and β-catenin in specimens of 54 breast cancer, 21 normal breast tissues around tumor, 15 breast hyperplasia of usual type and 15 breast atypical hyperplasia were detected by immunohistochemical method.
Results
In 21 normal breast tissues, E-cadherin and α-catenin were expressed on cell membrane of ductal and acinic cells, showing cellular contour and border among cells. The staining character of the three proteins in breast hyperplasia of usual type was the same as that in normal breast tissue. In breast atypical hyperplasia, the abnormal expression rates of E-cadherin, α-catenin and β-catenin were 6.7%, 13.3% and 26.7%, respectively. The total abnormal expression rate of E-cadherin-catenin complex was 33.3%. In breast cancer, the abnormal expression rates of E-cadherin, α-catenin and β-catenin were 51.9%, 63.0% and 61.1%, respectively. The total abnormal expression rate of E-cadherin-catenin complex was 88.9%. Abnormal expression of E-cadherin and α-catenin were significantly correlated with histological grade. Abnormal expressions of α-catenin and β-catenin were significantly correlated with TNM staging, axillary lymph nodes metastasis and postoperative distant metastasis. Abnormal expression of E-cadherin-catenin complex was correlated with TNM staging, histological grade and axillary lymph nodes. Abnormal expression of β-catenin was negatively correlated with expression of HER-2. COX multiple factor analysis showed that E-cadherin or α-catenin or β-catenin was not independent prognostic indicator.
Conclusion
Abnormal expressions of E-cadherin, α-catenin and β-catenin frequently occur in breast cancer. Abnormal expression of E-cadherin-catenin complex is correlated with differentiation disturbance and metastasis. Combined measurement of E-caherin, α-catenin and β-catenin may improve accuracy and sensitivity of predicting metastasis and prognosis of breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shimazui T, Schalken JA, Giroldi LA, et al. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors[J]. Cancer Res 1996; 56: 4154–4158.
Hugh TJ, Dillon SA, Taylor BA, et al. Cadherin-catenin expression in primary colorectal cancer: a survival analysis[J]. Br J Cancer 1999; 80:1046–1051.
He TC, Sparks AB, Rago C, et al. Identification of c-myc as a target of the APC pathway[J]. Science 1998; 281: 1509–1512.
Shtutman M, Zhurinsky J, Simcha I, et al. The cyclinD1 gene is a target of the β-catenin/LEF-1 pathway[J]. Proc Natl Acad Sci USA 1999; 96: 5522–5527.
Bankfalvi A, Terpe HJ, Breukelmann D, et al. Immunoplentypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumor progression: a comparative study with CD44[J]. Histopathology 1999; 34: 25–34.
Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary cancers of the breast and its distant metastasis[J]. Breast Cancer Res 2003; 5: 217–222.
Pedersen KB, Nesland JM, Fodstad Ø, et al. Expression of S100A4, E-cadherin, α-and β-catenin in breast cancer buiopsies[J]. Br J Cancer 2002; 87: 1281–1286.
Gabbert HE, Mueller W, Schneiders A, et al. Prognostic value of E-cadherin expression in 413 gastric cancers[J]. Int J Cancer 1996; 69: 184–189.
van de Wetering M, Barker N, Harkes IC, et al. Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling[J]. Cancer Res 2001; 61: 278–284.
Bullions LC, Notterman DA, Chung LS, et al. Expression of wild-type α-catenin gene restores both growth regulation and tumor suppressor activities[J]. Mol Cell Bio 1997; 17: 4501–4508.
Balsamo J, Leung T, Ernst H, et al. Regulated binding of PTP1B-like phosphatase to N-cadherin: control of cadherin-mediated adhesion by dephosphorylation of beta-catenin[J]. J Cell Biol 1996; 134: 801–813.
Brabletz T, Jung A, Dag S, et al. β-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer[J]. Am J Pathol 1999; 155: 1033–1038.
Gilles C, Polette M, Mestdagt M, et al. Transactivation of vimentin by β-catenin in human breast cancer cells[J]. Cancer Res 2003; 63: 2658–2664.
Lim SC, Lee MS. Significance of E-cadherin beta-catenin complex and cyclinD1 in breast cancer[J]. Oncol Rep 2002; 9: 915–928.
Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, et al. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival[J]. Histopathology 2002; 40: 536–546.
Author information
Authors and Affiliations
Corresponding author
Additional information
Biography: LIU Zhen (1973–), male, doctor of medicine, attending physician, the Second Affiliated Hospital, China Medical University, majors in general surgery.
Rights and permissions
About this article
Cite this article
Liu, Z., Cui, Dx., Liu, Bl. et al. Expression of E-cadherin/catenin complex in breast cancer. Chin. J. Cancer Res. 18, 299–305 (2006). https://doi.org/10.1007/s11670-006-0299-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11670-006-0299-z